UC-MSC Transplantation for Left Ventricular Dysfunction After AMI

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Left Ventricular DysfunctionAcute Myocardial Infarction
Interventions
BIOLOGICAL

UC-MSC

0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU, at the concentration of 2x10(7) cells/ml.

BIOLOGICAL

Control Group

Routine treatment without catheter infusion

Trial Locations (1)

200233

Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Jiao Tong University Affiliated Sixth People's Hospital

OTHER

lead

Shanghai Life Science & Technology

INDUSTRY

NCT03902067 - UC-MSC Transplantation for Left Ventricular Dysfunction After AMI | Biotech Hunter | Biotech Hunter